01:40:07 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-02-14 Bokslutskommuniké 2024
2024-11-14 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-30 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-03-01 X-dag ordinarie utdelning CSMED 0.00 DKK
2024-02-14 Bokslutskommuniké 2023
2023-12-15 X-dag ordinarie utdelning CSMED 0.00 DKK
2023-07-18 Kvartalsrapport 2023-Q3
2023-05-17 Kvartalsrapport 2023-Q2
2023-04-14 Extra Bolagsstämma 2023
2023-02-17 Kvartalsrapport 2023-Q1
2023-02-14 Årsstämma 2023
2023-02-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2022-11-18 Bokslutskommuniké 2022
2022-08-13 Kvartalsrapport 2022-Q3
2022-05-20 Kvartalsrapport 2022-Q2
2022-02-18 Kvartalsrapport 2022-Q1
2021-12-10 X-dag ordinarie utdelning CSMED 0.00 DKK
2021-12-09 Årsstämma 2022
2021-11-18 Bokslutskommuniké 2021


ListaSpotlight DK
IndustriLäkemedel & Handel
CS Medica är ett danskt medicintekniskt bolag, dedikerat till läkemedelsforskning, utveckling, tillverkning och global kommersialisering. Bolaget blandar vetenskap och natur för att förbättra patienters liv med cannabinoidterapier för smärtlindring, och för att hantera autoimmuna och stressrelaterade symtom. Globalt erbjuder CS Medica CBD-behandlingar över disk (OTC), inklusive patenterade medicinska produkter, MHRA och MDR-registrerade artiklar, under varumärket CANNASEN® eller med egen märkning.
2023-05-26 11:28:10

CS MEDICA A/S will deliver 45.500 pain patches in July to customers and thus faster than expected and have signed new distributors in new regions with an estimated order value of 5.6M DKK in the first contract year.

CS MEDICA A/S ("CS MEDICA" or the "Company") is happy to announce that the order intake from Q1 on the Pain Patch is ready for delivery in July, with an approximately two months shorter lead time than last year orders. Hence the company's new own-label customers in Italy (Montefamarco), Austria (BioBloom), and existing customer Forbe Health in Israel will receive the 45.500 products in total within two months, which will have a positive effect on CS MEDICA's cash flow.

Lone Henriksen, CEO CS MEDICA, comments 

 "It is very positive to witness the effect from our improved processes which not only benefits our customers, but also CS MEDICA's cash flow".

New European and APAC distributors
CS Medica has signed new, strong distributors in Balkan and Australia for the entire CANNASEN® line of products. 

  • PalcoNutrifit has a strong foothold in the Balkan markets of Croatia, Serbia, Bosnia, and Montenegro and will assist in speeding up the product registration outside the EU. The first-year contract value is 2.6M DKK.

  • ICON Medipharm is an international and prominent distributor and wholesaler of pharmaceutical and medical consumables in Australia with 3,500 pharmaceutical products and 1,500+ medical supply products. ICON Medipharm further supplies cannabis clinics in Brisbane and will assist with the local registration of the CANNASEN® products. ICON Medipharm's network also includes the UK, the EU region, and South East Asia allowing expanding the relationship further after Australia is launched. The first-year contract value is 3M DKK.

Lone Henriksen, CEO CS MEDICA, continues

 "We are proud to announce our presence in APAC (Asia Pacific) is growing with strong partners as this target region is one of the fastest growing within CBD and alternative OTC products. Furthermore, we are pleased that the European markets are actively requesting to distribute our branded products."

Outlook for 2022/23 is reiterated
The Company's expectations of year-to-date revenue growth of 120-130% from DKK 10.6M in 2021/22 and increased operating profits are reiterated.